LRRK2 and Parkinson disease: We suggest that our findings would not only support the effect of LRRK2 kinase inhibitors on dopaminergic neuronal loss due to αSyn-mediated neuroinflammation, but LRRK2-inhibitor administration might also provide a synergistic therapeutic effect against PD with αSyn propagation.